Ratings Westleaf Inc Toronto S.E.

Equities

End-of-day quote Toronto S.E. Other stock markets
- ^CAD	-

04-29	Decibel Cannabis Company Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-10	Fire & Flower Inc completed the acquisition of brick and mortar retail cannabis operations of Decibel Cannabis Company Inc.(TSXV:DB).	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Its low valuation, with P/E ratio at 4.8 and 2.67 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
With regards to fundamentals, the enterprise value to sales ratio is at 0.76 for the current period. Therefore, the company is undervalued.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
WESTLEAF INC	0.00%	35.93M		-
DONG-E-E-JIAO CO.,LTD.	+43.17%	6.16B		B-
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-14.69%	4.46B		C+
TASLY PHARMACEUTICAL GROUP CO., LTD	-8.17%	3.27B		B-
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+6.95%	3.2B		C
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-1.76%	2.6B	-	D+
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+50.20%	1.98B		-
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-7.85%	1.7B	-	-
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-0.40%	1.66B	-	-
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-9.91%	1.61B		C-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality